Dimensional Fund Advisors LP Grows Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Dimensional Fund Advisors LP lifted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 4.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 685,730 shares of the specialty pharmaceutical company's stock after purchasing an additional 30,420 shares during the quarter. Dimensional Fund Advisors LP owned about 3.26% of ANI Pharmaceuticals worth $37,906,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Canada Pension Plan Investment Board purchased a new stake in shares of ANI Pharmaceuticals during the fourth quarter valued at $1,697,000. Walleye Capital LLC purchased a new stake in ANI Pharmaceuticals during the 4th quarter valued at about $3,981,000. XTX Topco Ltd acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter valued at about $997,000. Barclays PLC raised its stake in shares of ANI Pharmaceuticals by 9.8% in the fourth quarter. Barclays PLC now owns 157,060 shares of the specialty pharmaceutical company's stock worth $8,682,000 after purchasing an additional 14,027 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of ANI Pharmaceuticals during the fourth quarter worth about $3,916,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the firm's stock in a transaction on Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the completion of the sale, the vice president now owns 80,145 shares of the company's stock, valued at $5,526,799.20. This trade represents a 0.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the transaction, the senior vice president now directly owns 68,624 shares in the company, valued at approximately $4,131,164.80. This trade represents a 1.44 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,200 shares of company stock valued at $197,792. 12.70% of the stock is currently owned by insiders.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ ANIP traded down $5.25 during mid-day trading on Friday, reaching $66.28. The company's stock had a trading volume of 665,638 shares, compared to its average volume of 319,256. The stock has a 50-day moving average of $66.71 and a two-hundred day moving average of $60.64. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The stock has a market capitalization of $1.44 billion, a P/E ratio of -120.51 and a beta of 0.56. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same period last year, the company posted $0.82 EPS. The business's revenue was up 43.4% on a year-over-year basis. On average, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on ANIP shares. JPMorgan Chase & Co. initiated coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price objective on the stock. Guggenheim reiterated a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Friday, April 11th. StockNews.com downgraded ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Thursday, April 24th. HC Wainwright reissued a "buy" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Finally, Jefferies Financial Group initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $80.13.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.